Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Autoinjector Warm-Up Time Pain Study
NCT05274087Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risankizumab in plaque psoriasis, Crohn's disease and psoriatic arthritis (PsA) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Change in Injection Site Pain Assessed Using Visual Analog Scale at 15 days and Percentage of Participants Experiencing Adverse Events at 155 days. Started Sep 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasisCrohn's diseasepsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05274087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274087.